ACC, AHA Release New Clinical Guidelines for Dyslipidemia Management

The American College of Cardiology (ACC) and American Heart Association (AHA) have released the updated 2026 guideline on dyslipidemia management, published in Circulation, introducing major changes in cardiovascular risk assessment and lipid treatment strategies.

Developed in collaboration with organizations such as the American Diabetes Association (ADA) and National Lipid Association (NLA), the guideline replaces the 2018 cholesterol recommendations and expands the focus to comprehensive lipid care. It emphasizes early detection, lifelong prevention, and management of not just cholesterol but also triglycerides and other lipid markers.

A key update is the introduction of the PREVENT Risk Calculator, which estimates 10- and 30-year cardiovascular risk in adults aged 30–79. This replaces older risk models and aims to improve risk prediction accuracy. The guideline also encourages earlier intervention, allowing lipid-lowering therapy to be considered even in individuals with borderline cardiovascular risk.

Importantly, specific treatment targets for Low-Density Lipoprotein Cholesterol (LDL-C) and non-HDL cholesterol have been reintroduced, providing clearer goals for clinicians. New biomarkers such as Apolipoprotein B (ApoB) and Lipoprotein(a) are now recommended for better risk assessment, with at least one lifetime Lp(a) measurement advised for all adults.

The guideline also broadens the use of Coronary Artery Calcium Scoring to guide treatment decisions. High-risk groups, including those with diabetes or chronic kidney disease, are advised to start lipid-lowering therapy regardless of baseline LDL levels.

For secondary prevention, more aggressive LDL-C targets below 55 mg/dL are recommended. While newer therapies exist, Statins remain the foundation of treatment, with additional options like ezetimibe and PCSK9 inhibitors used when needed.

REFERENCE: Blumenthal RS, Lloyd-Jones DM, Virani SS, et al. ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026.